SuperworthArtiva Biotherapeutics EPS ARTV
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$3.31
- Latest quarter, Q2 FY26
- −$0.63
- Fiscal year 2025
- −$3.43
Artiva Biotherapeutics' earnings per share was −$3.31 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.63.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.43 | n/a |
| FY2024 | −$40.82 | n/a |
| FY2023 | −$48.36 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.63 | n/a | −$3.31 | |
| Q1 FY26 | −$0.95 | n/a | −$3.55 | |
| Q4 FY25 | −$0.85 | n/a | −$3.43 | |
| Q3 FY25 | −$0.88 | n/a | −$3.24 | |
| Q2 FY25 | −$0.87 | n/a | −$3.28 | |
| Q1 FY25 | −$0.83 | n/a | −$24.41 | |
| Q4 FY24 | −$0.66 | n/a | −$40.82 | |
| Q3 FY24 | −$0.92 | −157% | −$54.99 | |
| Q2 FY24 | −$22.00 | n/a | −$52.45 | |
| Q1 FY24 | −$17.24 | n/a | −$44.54 | |
| Q4 FY23 | −$14.83 | n/a | −$48.36 | |
| Q3 FY23 | $1.62 | n/a | n/a |
Against its peers
Companies in Biotechnology nearest Artiva Biotherapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ARTVArtiva Biotherapeutics | −$3.31 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Artiva Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.